Menu
Menu
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology
NEW YORK – June 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS’s Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.
SOPHiA GENETICS and MSK bring unique strengths to the collaboration. SOPHiA DDM™, SOPHiA GENETICS's precision medicine platform, has been used to analyze more than 2.5 million cases since 2014, pioneering a unique, decentralized approach to precision oncology. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating an extensive genomic dataset linked to clinical outcomes, pathology, and radiology records.
The MOU envisions a precision medicine hub that would combine MSK's clinical data and expertise with SOPHiA GENETICS’s Ai platform to unlock a new approach to multimodal precision oncology.
For patients, the proposed precision medicine hub will act as an incubation studio for the discoveries of tomorrow, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide. The hub could move new discoveries from bench to clinical care faster than traditional models, expanding access to MSK’s oncology intelligence for patients across the globe.
For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.
The two institutions have a history of successful collaboration. Through previous license agreements involving MSK assays such as MSK-IMPACT® and MSK-ACCESS®, SOPHiA GENETICS has brought MSK diagnostics innovation to hospitals, labs, and patients in 35 countries across the globe using its platform SOPHiA DDMTM.
Although the specifics of this strategic initiative have yet to be finalized, it is envisioned that SOPHiA DDM™ would serve as the Ai and analytics platform of the precision medicine hub, supporting its data, Ai, and bioinformatics needs. MSK would contribute its clinical and scientific leadership, including support from its oncology faculty and exceptional ability to generate high-quality clinical data.
SOPHiA GENETICS’s announcement of this Memorandum of Understanding comes at a pivotal moment in oncology, as interest in Ai-enabled precision medicine continues to grow. New targeted cancer therapies are pushing molecular diagnostics earlier in the treatment pathway, creating demand for new diagnostic capabilities and scalable testing platforms. At the same time, Ai is emerging as a critical tool for clinical decision-making, making the combination of clinical data and Ai infrastructure one of the field's most strategic capabilities.
Ross Muken, President, SOPHiA GENETICS, said: "Our work with MSK has always been about extending the reach of MSK’s clinical intelligence, and this joint venture is the most ambitious expression of that mission yet. Over the past several years, we’ve built SOPHiA DDM™ into a foundational Ai and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with SOPHiA GENETICS's Ai platform and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK’s precision oncology to patients regardless of where they're treated.”
Michael G. Frank, Director of Digital Health Business Development at MSK, said: "This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge Ai and robotics with the potential to transform cancer care at scale. By combining MSK's deep clinical assets with SOPHiA GENETICS's powerful digital platform, we're seeking to create a new paradigm to deliver personalized insights to patients.”
# # #
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
San Diego, CA and New York, NY – April 16, 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities.
Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will leverage SOPHiA DDM™ to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.
By combining Mount Sinai’s clinical excellence with SOPHiA DDM™’s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.
Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: “The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”
John Carey, Managing Director, North America, SOPHiA GENETICS, said: “Mount Sinai is widely regarded as one of the world’s leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”
By utilizing the SOPHiA DDM™ for Blood Cancers and SOPHiA DDM™ for Solid Tumors applications, Mount Sinai joins a growing network of more than 990 global institutions using SOPHiA GENETICS’ decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS’ mission to democratize data-driven medicine, delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.
The collaboration was announced from the American Association for Cancer Research® (AACR) Annual Meeting in San Diego. Learn more by connecting with SOPHiA GENETICS at AACR booth #4248 from April 17 – 22, 2026.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.
About the Sumit
The decisions made in the next few years will define the trajectory of human health for decades to come. SOPHiA GENETICS brings together the pioneers making those decisions — clinicians, researchers, and biopharma leaders who refuse to accept the status quo.
Join us September 22–23, 2026 in Nashville for two immersive days at the intersection of AI, multimodal data, and precision medicine. Where bold ideas meet the real-world science to make them possible.
ATTENDEE VOICES
“Huge thanks to SOPHiA GENETICS for organizing this impactful event and for the opportunity to network with so many passionate leaders driving innovation in AI and life science.” – 2025 SUMMIT ATTENDEE
Save the date. Register your interest. Be part of what’s next.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
SOPHiA GENETICS is thrilled to return for ACMG 2026! Visit us at booth #1007 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Discover more about our newly launched extended pharmacogenomics (PGx) application, which covers HLA and mitochrondrial regions, with dedicated analytical modules that call variants from SNVs and CNvs to star alleles and CYP2D6/CVP2D7 gene conversion.
Learn more about SOPHiA DDM™ for whole genome sequencing and how our enhanced exome solutions detect challenging variants relevant for carrier screening, hereditary cancer, and PGx in one comprehensive application.
Exhibit Theater 1
Thursday March 12
12:30pm-1:00pm
Future-Ready Genomics: Real World Implementation and Validation from Hereditary Cancer to WGS
Dr. Francisco Perez Blanco, PhD, Chief of Molecular Diagnostics and Biometrics Laboratory, Clinical Alemana de Santiago
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Join this talk to hear real-world clinical experience, implementation, and validation insights, and performance data from SOPHiA DDM™ germline NGS applications, covering hereditary cancer, enhanced exomes, whole-genome sequencing, and pharmacogenomics.
Boston, MA, and Rolle, Switzerland, February 10, 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.
The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM™ to analyze complex genomic data at scale.
By adopting SOPHiA DDM™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.
Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.
John Carey, Managing Director, North America, SOPHiA GENETICS, said: “Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights.”
Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.
SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company’s mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn.
SOPHiA GENETICS is thrilled to be back at ASCO 2026! Meet our experts at booth #11111 to learn hear about our BioPharma solutions. Learn how to leverage our unique AI-powered data analytics and genomics expertise to accelerate late-stage clinical development programs. From diagnostic testing development & deployment, to insights and multimodal RWE, we are the right partner for pharma, enabling the advancement and commercialization of better precision therapies.
If you are attending this ASCO 2026 Annual Meeting, don’t miss our Poster presentation on Sunday, May 31st, from 9.00 am to 12.00 pm.
Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.
Loïc Ferrer, Senior Manager Multimodal R&D, SOPHiA GENETICS
SOPHiA GENETICS is thrilled to be back at AACR 2026! Visit us at booth #4248 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
If you are around, don’t miss our Poster presentation on Wednesday, April 22nd, from 9.00 am to 12.00 pm.
Poster #7820: CHIP detection in solid tumors differs between liquid biopsy testing approaches.
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Boston, MA and Houston, TX – January 7, 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.
As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test. Built on the advanced AI algorithms of the SOPHiA DDM™ Platform, the new co-developed test aims to translate complex multimodal data into actionable insights with greater speed and scale. MD Anderson researchers will tap SOPHiA GENETICS’ AI technologies to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide diagnosis and treatment for patients with cancer.
Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said: “Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information. This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”
In addition, MD Anderson and SOPHiA GENETICS will jointly launch a series of research and development programs to explore new ways to characterize tumor evolution in real time, to strengthen the reliability and reproducibility of complex genomic testing, and to enhance the ability to identify optimal clinical trials or research avenues for individual patients. This multi-layered program is designed to fuel next-generation scientific discovery, empowering clinicians and researchers with tools to better understand the dynamic nature of cancer. The collaborative work at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor, both in the Division of Pathology and Laboratory Medicine.
Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS, said: “This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research. With SOPHiA DDM™ as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.
Translating NGS Workflows into Real-World Impact in Hemato-Oncology
You are invited to join our networking event on hematologic malignancies during the 2025 Association of Molecular Pathologists Annual Meeting & Expo in Boston, USA.
Connect with peers and leading experts to explore how NGS-based solutions are advancing the investigation of complex variants in hematological malignancies.
During this event, speakers from renowned institutions will share real-world experiences implementing diverse NGS applications, including:
This is your opportunity to learn how peers are overcoming technical hurdles, realizing practical benefits, and applying NGS strategies to make genomic interpretation and decision-making in blood cancers more efficient.
What: Blood Cancer Showcase at AMP
Where: Omni Hotel - Marquee Room
Date: November 12th
Time: 6:30 pm – 8:15pm
Agenda to follow
Reserve your seat to this exclusive event on Wednesday, November 12th starting at 6:30 pm.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.